AR054989A1 - Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas - Google Patents

Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas

Info

Publication number
AR054989A1
AR054989A1 ARP050104849A AR054989A1 AR 054989 A1 AR054989 A1 AR 054989A1 AR P050104849 A ARP050104849 A AR P050104849A AR 054989 A1 AR054989 A1 AR 054989A1
Authority
AR
Argentina
Prior art keywords
trans
tetrahydrocanabinol
delta9
composition
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Ariel L Gutman
Gennady A Nisnevich
Igor Rukhman
Marina Etinger
Irina Fedotev
Boris Pertsikov
Ram Khanolkar
Boris Tishin
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054989(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR054989A1 publication Critical patent/AR054989A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

Métodos para producir trans-(-)-detal9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol son descritos en este documento. En una modalidad, una composicion trans-(-)-delt9-tetrahidrocanabinol es preparada al permitir que una composicion que comprende (-+)-delta9- tetrahidrocanabinol se separe en una fase quiral estacionaria para proporcionar una composicion trans-(-)delta9-tetrahidrocanabinol que comprende al menos alrededor de un 99% en peso de trans-(-)-delta9-tetrahidrocanabinol basado en la cantidad total de trans-(-)-delta9- tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol. También se refiere a métodos para tratar o prevenir una condicion tal como dolor, comprendiendo la administracion a un paciente, que necesite del mismo, una cantidad efectiva de un trans-(-)-delta9-tetrahidrocanabinol teniendo una pureza de al menos alrededor de 98%, basado en el peso total de canabinoides. Reivindicacion 1: Composicion de trans-(-)-delta9-tetrahidrocanabinol o trans-(+)- delta9-tetrahidrocanabinol, caracterizada porque la composicion trans-(-)-delta9-tetrahidrocanabinol comprende alrededor de al menos un 98% en peso de trans-(-)-delta9-tetra-hidrocanabinol, basado en la cantidad total de canabinoides y la composicion de trans-(+)-delta9-tetrahidrocanabinol comprende alrededor de al menos un 98% en peso de trans-(+)-delta9-tetrahidrocanabinol, basado en la cantidad total de canabinoides.
ARP050104849 2004-11-22 2005-11-18 Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas AR054989A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63055604P 2004-11-22 2004-11-22

Publications (1)

Publication Number Publication Date
AR054989A1 true AR054989A1 (es) 2007-08-01

Family

ID=35789123

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104849 AR054989A1 (es) 2004-11-22 2005-11-18 Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas

Country Status (31)

Country Link
US (6) US8383842B2 (es)
EP (3) EP2356987B1 (es)
JP (3) JP4995728B2 (es)
KR (1) KR100919719B1 (es)
CN (2) CN102151259A (es)
AR (1) AR054989A1 (es)
AT (1) ATE500824T1 (es)
AU (2) AU2005305944B2 (es)
BR (1) BRPI0519803A2 (es)
CA (2) CA2921590C (es)
CY (1) CY1111471T1 (es)
DE (1) DE602005026852D1 (es)
DK (3) DK2289509T3 (es)
EA (1) EA012299B1 (es)
ES (3) ES2556802T3 (es)
HK (3) HK1109058A1 (es)
HR (3) HRP20110385T1 (es)
HU (2) HUE027197T2 (es)
IL (1) IL183306A (es)
ME (2) ME02306B (es)
MX (1) MX2007006104A (es)
NO (1) NO331831B1 (es)
NZ (1) NZ556038A (es)
PL (3) PL2289509T3 (es)
PT (2) PT2289509E (es)
RS (3) RS54338B1 (es)
SI (3) SI2356987T1 (es)
TW (2) TWI436991B (es)
UA (1) UA88491C2 (es)
WO (1) WO2006053766A1 (es)
ZA (1) ZA200706837B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI436991B (zh) 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-(-)-△9-四氫大麻酚與反-(+)-△9-四氫大麻酚之方法
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007041167A2 (en) 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
GB0702895D0 (en) * 2007-02-14 2007-03-28 Resolution Chemicals Ltd Delta 9 tetrahydrocannabinol derivatives
GB0703284D0 (en) * 2007-02-20 2007-03-28 Resolution Chemicals Ltd Delta 9 - tetrahydrocannabinol processing
WO2009099868A1 (en) * 2008-02-06 2009-08-13 Mallinckrodt Inc. Process for the preparation of (-) -delta 9-tetrahydrocannabinol
US10624859B2 (en) 2012-08-20 2020-04-21 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
CA3111682A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
US10155708B2 (en) * 2015-01-22 2018-12-18 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
US11034639B2 (en) 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
US10207198B2 (en) 2015-01-22 2019-02-19 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
CN106268657A (zh) * 2015-05-14 2017-01-04 株式会社大赛璐 光学异构体用分离剂
US10059683B2 (en) 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
PL3455213T3 (pl) * 2016-05-13 2022-04-04 Symrise Ag Sposób oczyszczania związków kannabinoidowych przez symulowaną chromatografię z ruchomym złożem
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN106810426B (zh) * 2016-12-29 2020-05-08 暨明医药科技(苏州)有限公司 一种大麻二酚的合成方法
US11213558B2 (en) 2017-05-17 2022-01-04 Orochem Technologies, Inc. CBX extraction-isolation process
US10189762B1 (en) * 2017-07-07 2019-01-29 Orochem Technologies, Inc. Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves
SG11202001725SA (en) * 2017-09-01 2020-03-30 Pureform Global Inc Synthetic cannabidiol compositions and methods of making the same
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US11192870B2 (en) 2018-03-07 2021-12-07 Socati Technologies—Oregon, Llc Continuous isolation of cannabidiol and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
US11851415B2 (en) 2018-03-07 2023-12-26 Cleen Technology Inc. Continuous isolation of cannabidiol and cannabinoids and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
CN112105606A (zh) * 2018-03-07 2020-12-18 索卡蒂科技俄勒冈有限公司 大麻素的连续分离以及大麻素向δ8-四氢大麻酚和δ9-四氢大麻酚的转化
US11485700B2 (en) * 2018-06-28 2022-11-01 Symrise Ag Synthesis of (+)-cannabinoids and their therapeutic effects
CA3073093A1 (en) 2018-08-03 2020-02-06 Biomass Oil Separation Solutions, Llc Processes and apparatus for extraction of substances and enriched extracts from plant material
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
JP2022512777A (ja) 2018-10-31 2022-02-07 エナンティア,エセ.エレ. カンナビノイドの共結晶の固体組成物
EP3653596A1 (en) 2018-11-14 2020-05-20 Indena S.p.A. Continuous flow synthesis of cannabidiol
CN109734554B (zh) * 2019-02-25 2021-11-23 江苏暨明医药科技有限公司 一种反式-薄荷基-2,8-二烯-1-醇的合成工艺
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
WO2020248062A1 (en) * 2019-06-11 2020-12-17 Canopy Growth Corporation Improved methods for cannabinoid isomerization
US10799546B1 (en) 2019-07-26 2020-10-13 Biomass Oil Separation Solutions, Llc Modular, integrated process and apparatus for extracting, refining and remediating active substances from plant material
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
CA3158415A1 (en) * 2019-10-21 2021-04-29 Esolate Ltd Compositions comprising superfine compounds and production thereof
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB2588457B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
US20220340507A1 (en) 2020-03-12 2022-10-27 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Process for the synthesis of cannabidiol and intermediates thereof
CN113336705B (zh) * 2021-08-09 2021-12-10 中国农业科学院农产品加工研究所 一种大麻二酚-2-咪唑-1-甲酸酯及其应用
WO2024028516A1 (en) 2022-08-05 2024-02-08 Salud & Semillas, S.L. CANNABINOID SYNTHESIS STARTING OUT FROM OLIVETOL AND TERPENE IN DICHLOROMETHANE WITH FeCl3 * 6H2O AS CATALYST
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技(苏州)有限公司 一种高纯度四氢大麻素同系物的制备方法
CN115784836A (zh) * 2022-12-08 2023-03-14 南京康立瑞生物科技有限公司 一种高选择性的制备反式-薄荷基-2,8-二烯-1-醇的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507885A (en) 1966-03-25 1970-04-21 Hoffmann La Roche 3-alkyl-6h-dibenzo(b,d)pyrans
CH481911A (de) 1967-05-19 1969-11-30 Theodor Dr Petrzilka Verfahren zur Herstellung von tricyclischen Verbindungen
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US4025516A (en) 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4381399A (en) 1981-12-21 1983-04-26 Aerojet-General Corporation Purification of tetrahydrodibenzo[b,d]pyrans from crude synthetic mixtures
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US6703418B2 (en) 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP0833622B8 (en) 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6730519B2 (en) 1998-10-26 2004-05-04 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US6365416B1 (en) 1998-10-26 2002-04-02 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
FI990915A0 (fi) 1999-04-23 1999-04-23 Orion Yhtymae Oyj Jauheinhalaattori
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
GB2368061B (en) 2000-10-20 2005-05-11 Gw Pharmaceuticals Ltd Dose dispensing apparatus
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
WO2002070506A2 (en) 2001-03-07 2002-09-12 Websar Innovations Inc. Conversion of cbd to δ8-thc and δ9-thc
US20030050334A1 (en) 2001-04-30 2003-03-13 Murty Ram B. Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
NZ552547A (en) * 2002-02-01 2008-03-28 Resolution Chemicals Ltd Production of Delta 9 tetrahydrocannabinol from plant material
AU2002242779A1 (en) 2002-02-21 2003-09-09 Timothee Biel Device for driving motor vehicles, in particular with hybrid propulsion
UA79281C2 (en) 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CA2770448C (en) 2002-11-12 2014-03-25 Prairie Plant Systems Inc. Cannabinoid esters
US20040229939A1 (en) 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
CA2544900A1 (en) 2003-11-05 2005-05-19 Unimed Pharmaceuticals, Inc. Delta-9- the treatment of multiple sclerosis
GB0329635D0 (en) 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
EP1773801A1 (de) 2004-07-19 2007-04-18 Cilag Ltd. Verfahren zur gewinnung von reinem tetrahydrocannabinol
GB0425445D0 (en) 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
TWI436991B (zh) * 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-(-)-△9-四氫大麻酚與反-(+)-△9-四氫大麻酚之方法
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2009018389A1 (en) 2007-07-30 2009-02-05 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
US8642645B2 (en) * 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids

Also Published As

Publication number Publication date
MX2007006104A (es) 2007-07-11
US9278083B2 (en) 2016-03-08
HK1109058A1 (en) 2008-05-30
CY1111471T1 (el) 2015-08-05
AU2010200227A1 (en) 2010-02-11
CN102151259A (zh) 2011-08-17
UA88491C2 (ru) 2009-10-26
HK1159500A1 (en) 2012-08-03
EA012299B1 (ru) 2009-08-28
US20150126596A1 (en) 2015-05-07
SI2356987T1 (sl) 2016-04-29
ES2566480T3 (es) 2016-04-13
NO20072964L (no) 2007-08-17
PT2289509E (pt) 2015-12-23
KR20070086529A (ko) 2007-08-27
JP5048448B2 (ja) 2012-10-17
ES2556802T3 (es) 2016-01-20
WO2006053766A1 (en) 2006-05-26
NO331831B1 (no) 2012-04-16
JP4995728B2 (ja) 2012-08-08
PL2289509T3 (pl) 2016-04-29
ZA200706837B (en) 2008-04-30
PT1824475E (pt) 2011-06-01
NZ556038A (en) 2009-12-24
RS51706B (en) 2011-10-31
DE602005026852D1 (de) 2011-04-21
HRP20160300T1 (hr) 2016-04-22
BRPI0519803A2 (pt) 2009-03-17
WO2006053766A8 (en) 2006-12-14
US8383842B2 (en) 2013-02-26
EP2289509A2 (en) 2011-03-02
CA2921590A1 (en) 2006-05-26
DK2289509T3 (en) 2015-11-23
TWI369203B (en) 2012-08-01
US9675581B2 (en) 2017-06-13
EP2356987B1 (en) 2016-01-06
SI2289509T1 (sl) 2016-01-29
EA200701123A1 (ru) 2007-12-28
DK2356987T3 (en) 2016-03-21
IL183306A0 (en) 2007-09-20
EP1824475A1 (en) 2007-08-29
AU2005305944B2 (en) 2010-03-04
US20130171259A1 (en) 2013-07-04
RS54537B1 (en) 2016-06-30
IL183306A (en) 2012-06-28
TW200633695A (en) 2006-10-01
CN101076329B (zh) 2011-08-10
JP2008101000A (ja) 2008-05-01
US20160199344A1 (en) 2016-07-14
DK1824475T3 (da) 2011-06-06
JP2008520608A (ja) 2008-06-19
SI1824475T1 (sl) 2011-06-30
RS54338B1 (en) 2016-02-29
US20160184261A1 (en) 2016-06-30
KR100919719B1 (ko) 2009-10-06
US9744151B2 (en) 2017-08-29
HRP20110385T1 (hr) 2011-06-30
CA2921590C (en) 2019-09-24
TWI436991B (zh) 2014-05-11
CA2587957C (en) 2016-05-03
EP2356987A1 (en) 2011-08-17
ME02306B (me) 2016-06-20
CA2587957A1 (en) 2006-05-26
ES2362288T3 (es) 2011-06-30
PL1824475T3 (pl) 2011-09-30
US8937097B2 (en) 2015-01-20
HRP20151301T1 (hr) 2016-01-01
EP2289509B1 (en) 2015-10-14
EP1824475B1 (en) 2011-03-09
US20090298930A1 (en) 2009-12-03
ME02403B (me) 2016-09-20
HUE025904T2 (en) 2016-05-30
US20160184260A1 (en) 2016-06-30
HK1154796A1 (en) 2012-05-04
CN101076329A (zh) 2007-11-21
EP2289509A3 (en) 2011-08-10
HUE027197T2 (en) 2016-10-28
AU2005305944A1 (en) 2006-05-26
JP2012180350A (ja) 2012-09-20
TW201302722A (zh) 2013-01-16
ATE500824T1 (de) 2011-03-15
PL2356987T3 (pl) 2016-09-30

Similar Documents

Publication Publication Date Title
AR054989A1 (es) Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
DK1572194T3 (da) Anti-cancersammensætning indeholdende DMXAA
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
ECSP088208A (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
GT200500107A (es) Derivados de fenol y tiofenol 3-0 4-monosustituidos utiles como ligandos de h3
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
UY28945A1 (es) Derivados de pirrolopiridina
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
AR109263A2 (es) Composición que comprende moxidectina
BR112013025878A2 (pt) composição farmacêutica e método para produzir uma composição farmacêutica
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
CO6640244A2 (es) Composiciones farmacéuticas tópicas
PA8651401A1 (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
BRPI0412928A (pt) dibenzo[b,f]oxepina-10-carboxamidas e usos farmacêuticos das mesmas
NI201200196A (es) Agentes terapéuticos 976
AR067863A1 (es) Composiciones que contienen una mezcla sinergica de polioles y de xiloglucanos como productos fitosanitarios y biofertilizantes

Legal Events

Date Code Title Description
FC Refusal